Literature DB >> 16547596

Cell death regulation by B-cell lymphoma protein.

Y K Verma1, G U Gangenahalli, V K Singh, P Gupta, R Chandra, R K Sharma, H G Raj.   

Abstract

Bcl-2 (B Cell Lymphoma) protein is an anti-apoptotic member of Bcl-2 family, which is comprised of pro- and anti-apoptotic members. It regulates cellular proliferation and death by inter- and intra-family interactions. It has a potential to suppress apoptotic cell death under variety of stress conditions by modulating mitochondrial transmembrane potential. However, prevalence of constitutively activated Bcl-2 cellular activity is not always required in cells; a mechanism likely exists in cells, which controls its activity. When expression of Bcl-2 is unregulated, it generates lymphoma like, follicular B-cell lymphoma. This article reviews the structural and functional regulation of Bcl-2 activity at transcriptional, translational, domain, structural and post-translational level, which also accounts for the effects of its deletion and site-directed mutants in the regulation of cellular proliferation and differentiation in vitro and in vivo. This concisely reviewed information on Bcl-2 helps us to update our understanding of cell death and its modulation by Bcl-2 and its mutant's interaction, which has gained therapeutic benefits in cell growth and proliferation, particularly for sensitive human hematopoietic stem cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547596     DOI: 10.1007/s10495-006-5702-1

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  8 in total

1.  Verrucarin A alters cell-cycle regulatory proteins and induces apoptosis through reactive oxygen species-dependent p38MAPK activation in the human breast cancer cell line MCF-7.

Authors:  Kandasamy Palanivel; Veerasamy Kanimozhi; Balamuthu Kadalmani
Journal:  Tumour Biol       Date:  2014-07-16

2.  Molecular dynamics simulations of the Bcl-2 protein to predict the structure of its unordered flexible loop domain.

Authors:  Pawan Kumar Raghav; Yogesh Kumar Verma; Gurudutta U Gangenahalli
Journal:  J Mol Model       Date:  2011-08-25       Impact factor: 1.810

3.  Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27(Kip1)-dependent G1/S cell cycle arrest in conjunction with NF-kappaB activation.

Authors:  Christina Batsi; Soultana Markopoulou; Evangelos Kontargiris; Christiana Charalambous; Christoforos Thomas; Savvas Christoforidis; Panagiotis Kanavaros; Andreas I Constantinou; Kenneth B Marcu; Evangelos Kolettas
Journal:  Biochem Pharmacol       Date:  2009-03-27       Impact factor: 5.858

4.  Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.

Authors:  Yuan Sun; Jack Wu; Amro Aboukameel; Sanjeev Banerjee; Alan A Arnold; Jianyong Chen; Zaneta Nikolovska-Coleska; Yanqiong Lin; Xiaolan Ling; Dajun Yang; Shaomeng Wang; Ayad Al-Katib; Ramzi M Mohammad
Journal:  Cancer Biol Ther       Date:  2008-09-04       Impact factor: 4.742

5.  Effects of lithium and deafferentation on expression of glycogen synthase kinase-3beta, NFkappaB, beta-catenin and pCreb in the chick cochlear nucleus.

Authors:  Angela L Bush; Richard L Hyson
Journal:  Brain Res       Date:  2008-02-09       Impact factor: 3.252

6.  BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Authors:  Daniel B Costa; Balázs Halmos; Amit Kumar; Susan T Schumer; Mark S Huberman; Titus J Boggon; Daniel G Tenen; Susumu Kobayashi
Journal:  PLoS Med       Date:  2007-10       Impact factor: 11.069

7.  Bcl-2 regulates store-operated Ca2+ entry to modulate ER stress-induced apoptosis.

Authors:  Wen-Tai Chiu; Heng-Ai Chang; Yi-Hsin Lin; Yu-Shan Lin; Hsiao-Tzu Chang; Hsi-Hui Lin; Soon-Cen Huang; Ming-Jer Tang; Meng-Ru Shen
Journal:  Cell Death Discov       Date:  2018-02-26

8.  Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.

Authors:  Sung-Young Shin; Anna-Katharina Müller; Nandini Verma; Sima Lev; Lan K Nguyen
Journal:  PLoS Comput Biol       Date:  2018-06-19       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.